BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Sanofi  Pasteur  MSD,  SNC  submitted  on  26  April  2005  an  application  for  Marketing 
Authorization  to  the  European  Medicines  Agency  (EMEA)  for  RotaTeq,  through  the  centralized 
procedure  under  Article  3  (2)  a  of  Regulation  (EC)  No  726/2004.  The  eligibility  to  the  centralized 
procedure was agreed upon by the EMEA/CHMP on 21 January 2005. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: 
Ian Hudson 
Co-Rapporteur:  Bengt Ljungberg 
Licensing status: 
 The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
•  The application was received by the EMEA on 26 April 2005. 
•  The procedure started on 18 May 2005.  
•  The Rapporteur's first Assessment Report was circulated to all CHMP members on 18 July 2005. 
The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  26  July 
2005.  
• 
 During  the  meeting  on  12-15  September  2005,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions  to  be  sent  to  the  applicant.  The  final  consolidated  List  of  Questions  was  sent  to  the 
applicant on 15 September 2005. 
•  The applicant submitted the responses to the CHMP consolidated List of Questions on  
 12 December 2005. 
•  The summary report of the inspection carried out at the following site: Merck & Co Inc. between  
9-13 January 2006 was issued on 27 February 2006. 
•  The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List of 
Questions to all CHMP members on 20 January 2006. 
•  During  the  CHMP  meeting  on  20-23  February  2006,  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing by the applicant. 
•  On 17 March 2006 outstanding issues were addressed by the applicant in writing. 
•  During a meeting of a Biologics Working Party on 05-07 September 2005, 13-15 February 2006 
and 19-20 April 2006 experts were convened to address questions raised by the CHMP. 
•  During the meeting on 24-27 April 2006, the CHMP, in the light of the overall data submitted and 
the scientific discussion within the Committee, issued a positive opinion for granting a Marketing 
Authorisation to RotaTeq on 27 April 2006. The applicant provided the letter of undertaking on the 
follow-up measures to be fulfilled post-authorisation on 27 April 2006. 
•  The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 27 June 2006. 
1/1 
©EMEA 2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
